The associations of IL-18 serum levels and promoter polymorphism with tacrolimus pharmacokinetics and hepatic allograft dysfunction in Chinese liver transplantation recipients.

[1]  Minna Männikkö,et al.  The Collagen V Homotrimer [α1(V)]3 Production Is Unexpectedly Favored over the Heterotrimer [α1(V)]2α2(V) in Recombinant Expression Systems , 2010, Journal of biomedicine & biotechnology.

[2]  F. Russel,et al.  Regulation of P-Glycoprotein in Renal Proximal Tubule Epithelial Cells by LPS and TNF-α , 2010, Journal of biomedicine & biotechnology.

[3]  S. Uemoto,et al.  Prospective Evaluation of the Bayesian Method for Individualizing Tacrolimus Dose Early After Living‐Donor Liver Transplantation , 2009, Journal of clinical pharmacology.

[4]  P. Anzenbacher,et al.  Current status and challenges of cytokine pharmacology , 2009, British journal of pharmacology.

[5]  Y. Chen,et al.  Association of interleukin-18 promoter polymorphisms with WHO pathological classes and serum IL-18 levels in Chinese patients with lupus nephritis , 2009, Lupus.

[6]  J. Chapman,et al.  Individualization of immunosuppression: concepts and rationale , 2008, Current opinion in organ transplantation.

[7]  M. Filipenko,et al.  Association of Single Nucleotide Polymorphisms in the IL-18 Gene with Production of IL-18 Protein by Mononuclear Cells from Healthy Donors , 2008, Mediators of inflammation.

[8]  G. Burckart,et al.  Effect of cytokine and pharmacogenomic genetic polymorphisms in transplantation. , 2008, Current opinion in immunology.

[9]  N. Perico,et al.  Pharmacogenetics of Immunosuppressants: Progress, Pitfalls and Promises , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  P. Beaune,et al.  Role of Pharmacogenetics of Immunosuppressive Drugs in Organ Transplantation , 2008, Therapeutic drug monitoring.

[11]  H. Valantine,et al.  Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  Dan Li,et al.  Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL‐10 polymorphisms in adult liver transplant patients , 2007, Journal of clinical pharmacy and therapeutics.

[13]  Guo-liang Zhang,et al.  Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[14]  H. Strobel,et al.  Catalytic characterization and cytokine mediated regulation of cytochrome P450 4Fs in rat hepatocytes. , 2007, Archives of biochemistry and biophysics.

[15]  G. Fricker,et al.  Rapid Modulation of P-Glycoprotein-Mediated Transport at the Blood-Brain Barrier by Tumor Necrosis Factor-α and Lipopolysaccharide , 2006, Molecular Pharmacology.

[16]  J. Lácha,et al.  Interleukin 18 (IL-18) upregulation in acute rejection of kidney allograft. , 2005, Immunology letters.

[17]  J. Prandota.  Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology. , 2005, American journal of therapeutics.

[18]  D. Buckley,et al.  Nitric oxide mediates increased P-glycoprotein activity in interferon-{gamma}-stimulated human intestinal cells. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[19]  B. Griffith,et al.  Tacrolimus Dosing in Adult Lung Transplant Patients Is Related to Cytochrome P4503A5 Gene Polymorphism , 2004, Journal of clinical pharmacology.

[20]  M. Ingelman-Sundberg,et al.  Mechanisms of Down-Regulation of CYP2E1 Expression by Inflammatory Cytokines in Rat Hepatoma Cells , 2003, Journal of Pharmacology and Experimental Therapeutics.

[21]  J. Castell,et al.  Down‐regulation of human CYP3A4 by the inflammatory signal interleukin 6: molecular mechanism and transcription factors involved , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  B. Lacour,et al.  Effect of hr‐IL2 treatment on intestinal P‐glycoprotein expression and activity in Caco‐2 cells , 2002, The Journal of pharmacy and pharmacology.

[23]  R. Wiesner,et al.  Late hepatic allograft dysfunction , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[24]  M. Sukhai,et al.  Decreased expression of P-glycoprotein in interleukin-1β and interleukin-6 treated rat hepatocytes , 2001, Inflammation Research.

[25]  H. Okamura,et al.  Interleukin-18 regulates both Th1 and Th2 responses. , 2001, Annual review of immunology.

[26]  F. Thévenod,et al.  Up-regulation of Multidrug Resistance P-glycoprotein via Nuclear Factor-κB Activation Protects Kidney Proximal Tubule Cells from Cadmium- and Reactive Oxygen Species-induced Apoptosis* , 2000, The Journal of Biological Chemistry.